NSE ScannerFMCG & Food · Household/Personal Care · NSE: JHS · data 2026-10-30
JHS Svendgaard Laboratories Limited
In plain words
Price: 41.6% below its 52-week high of ₹13.69.
Delivery: 59.6% of traded shares were kept for delivery over the last 10 sessions, against 72.0% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹109 cr |
| Net profit (last 12 months) | ₹-2 cr |
| Sales growth, 3 years (yearly) | 6.2% |
| Profit growth, 3 years (yearly) | — |
Latest results in brief (Q2 FY25)
JHS Q2 FY25 results (consolidated figures, as filed on NSE).
Revenue was ₹19.68 crore, up 4% YoY and down 19.6% QoQ.
Net loss was ₹10.32 crore, a bigger loss than a year ago and a bigger loss than last quarter.
Operating margin was 4.3% (2.1% a year ago).
EPS was -₹1.24, more negative than a year ago and more negative than last quarter.
JHS के Q2 FY25 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹19.68 करोड़; पिछले साल की तुलना में 4% की बढ़त, पिछली तिमाही की तुलना में 19.6% की गिरावट।
शुद्ध घाटा: ₹10.32 करोड़; एक साल पहले से घाटा बढ़ा, पिछली तिमाही से घाटा बढ़ा।
ऑपरेटिंग मार्जिन: 4.3% (एक साल पहले 2.1%)।
EPS: -₹1.24; एक साल पहले से अधिक ऋणात्मक, पिछली तिमाही से अधिक ऋणात्मक।
JHSના Q2 FY25 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹19.68 કરોડ; ગયા વર્ષની સરખામણીએ 4% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 19.6% ઘટાડો.
ચોખ્ખી ખોટ: ₹10.32 કરોડ; એક વર્ષ પહેલાંની સરખામણીએ ખોટ વધી, ગયા ક્વાર્ટરની સરખામણીએ ખોટ વધી.
ઓપરેટિંગ માર્જિન: 4.3% (એક વર્ષ પહેલાં 2.1%).
EPS: -₹1.24; એક વર્ષ પહેલાંના કરતાં વધુ નકારાત્મક, ગયા ક્વાર્ટરના કરતાં વધુ નકારાત્મક.
Written from the filed numbers. Not a recommendation.
Smart-money activity
9/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: Net −₹0.64 cr in bulk/block deals over 90 days (0 net buying days, 1 net selling day): more sold than bought.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Results
- 1 Oct 26Deal Bulk deal: BHIM SAIN BASSI sold ₹0.64 cr -15.4% next session
- 14 Nov 24Results Q2 FY25 results: loss widened vs a year ago -4.5% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Common questions
Is JHS Svendgaard Laboratories Limited debt-free?
Its latest reported debt-to-equity ratio is 0.09, which is very low.
What is the 52-week high and low of JHS Svendgaard Laboratories Limited?
The 52-week high is ₹13.69 and the 52-week low is ₹6.26.
Similar companies
Bajaj Consumer Care Limited (BAJAJCON) · Sacheerome Limited (SACHEEROME) · Kaya Limited (KAYA) · Dhariwalcorp Limited (DHARIWAL) · Medistep Healthcare Limited (MEDISTEP)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open JHS in NSE Scanner →